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Abstract
Background: Iron-refractory iron deficiency anaemia (IRIDA) is a rare disorder which was linked to mutations in two genes
(SLC11A2 and TMPRSS6). Common polymorphisms within these genes were associated with serum iron levels. We identified
a family of Serbian origin with asymptomatic non-consanguineous parents with three of four children presenting with IRIDA
not responding to oral but to intravenous iron supplementation. After excluding all known causes responsible for iron
deficiency anaemia we searched for mutations in SLC11A2 and TMPRSS6 that could explain the severe anaemia in these
children.
Methodology/Results: We sequenced the exons and exon–intron boundaries of SLC11A2 and TMPRSS6 in all six family
members. Thereby, we found seven known and fairly common SNPs, but no new mutation. We then genotyped these seven
SNPs in the population-based SAPHIR study (n=1,726) and performed genetic association analysis on iron and ferritin levels.
Only two SNPs, which were top-hits from recent GWAS on iron and ferritin, exhibited an effect on iron and ferritin levels in
SAPHIR. Six SAPHIR participants carrying the same TMPRSS6 genotypes and haplotype-pairs as one anaemic son showed
lower ferritin and iron levels than the average. One individual exhibiting the joint SLC11A2/TMPRSS6 profile of the anaemic
son had iron and ferritin levels lying below the 5
th percentile of the population’s iron and ferritin level distribution. We then
checked the genotype constellations in the Nijmegen Biomedical Study (n=1,832), but the profile of the anaemic son did
not occur in this population.
Conclusions: We cannot exclude a gene-gene interaction between SLC11A2 and TMPRSS6, but we can also not confirm it. As
in this case candidate gene sequencing did not reveal causative rare mutations, the samples will be subjected to whole
exome sequencing.
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Introduction
Iron deficiency is a global health concern and usually attributed
to chronic blood loss or inadequate dietary iron intake [1]. In rare
cases iron deficiency can be referred to insufficient duodenal iron
absorption which cannot be sufficiently treated by oral iron
supplementation. This type of anaemia is termed iron-refractory
iron-deficiency anaemia (IRIDA) and is an autosomal-recessive
disorder, characterized by (i) congenital, hypochromic, microcytic
anaemia; (ii) very low mean corpuscular volume (MCV); (iii) low
serum iron and low transferrin saturation; (iv) normal ferritin or
ferritin levels in the lower limits of normal; (v) no response to oral
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[2,3].
At the luminal side of the gut dietary iron is transferred into the
enterocyte by the divalent metal transporter 1 (DMT1, SLC11A2)
[4]. SLC11A2 (solute carrier family 11 (proton-coupled divalent
metal ion transporters), member 2) also transfers iron from the
endosomes to the cytosol following the uptake of iron via a
transferrin receptor complex, is also of importance for the shuttling
of iron in several tissues such as the liver or kidney and importantly
for the transfer of iron taken up via transferrin receptor mediated
endocytosis from the endosome into the cytoplasm [4–6].
Dysregulation of SLC11A2 can lead to disturbances of iron
homeostasis. For example, activation of SLC11A2 in the brain was
associated with toxic iron accumulation, autophagy and cell death
in mouse models of Parkinson disease [7] whereas pharmacolog-
ical modulation of SLC11A2 activity can reverse hepatic iron
overload in mouse models of hemochromatosis [4]. Importantly, a
loss of function mutation was responsible for the development of
severe microcytic anaemia in mk/mk mice [6]. Subsequently,
several rare mutations in SLC11A2 were identified and were linked
to the development of microcytic anaemia in a total of 4 patients
[8–11]. Interestingly, such patients present with low serum ferritin
levels but normal or increased transferrin saturation along with
low hepcidin concentrations [8–12].
TMPRSS6 (transmembrane serine protease 6) mutations were
described to cause IRIDA [13–16]. TMPRSS6 encodes for
matriptase-2, a type II transmembrane serine protease mainly
produced by the liver. TMPRSS6 belongs to a large group of type
two serine proteases which modulate a variety of cellular processes
including the selective cleavage of specific substrates which is
fulfilled by a conserved catalytic motif. Type two serine proteases
act as membrane bound proteases, however, soluble forms – as for
TMPRSS6 – have also been described. Accordingly, TMPRSS6
expression is increased in early embryogenesis and mislocalization
of this protease has been associated with high grade prostate
cancer [17].
Recently, TMPRSS6 has been identified as a modifier of iron
homeostasis because it regulates the expression of the systemic iron
regulatory hormone hepcidin [18] and inhibits hepcidin activation
by cleaving membrane hemojuvelin [19]. Hepcidin controls iron
absorption by binding to the only known cellular iron export
protein ferroportin thereby leading to ferroportin degradation and
blockage of iron egress from the enterocyte into the circulation
[18,20]. In addition, hepcidin blocks the transfer of iron from
macrophages into the circulation, which is the major iron source
for erythropoiesis following erythrophagocytosis and re-utilization
of the metal from senescent erythrocytes [20–22]. Thus, under
physiologic conditions high levels of hepcidin as observed with iron
overload reduce iron absorption from the diet. In iron deficiency,
however, low iron levels inhibit hepcidin formation and thus
enables iron to be transferred from the gut to the blood [18]. Part
of the iron-mediated control of hepcidin can be referred to the
action of TMPRSS6 and thus functional mutations in this gene are
associated with insufficient iron absorption on the basis of
increased hepcidin levels [13–16]. In addition, in genome-wide
association studies (GWAS) common variants in TMPRSS6 were
associated with alterations of serum iron status, erythrocyte
volume [23–25], or hemoglobin levels [26,27].
We identified a family with asymptomatic non-consanguineous
parents with three of four children presenting with severe anaemia.
After excluding all known causes responsible for iron deficiency
anaemia we searched for mutations in SLC11A2 and TMPRSS6
that could explain the severe anaemia in these children.
Materials and Methods
Patient characteristics and evaluation of anaemia
We describe a family of Serbian origin with asymptomatic non-
consanguineous parents and three out of four children suffering
from IRIDA (Table 1). This disease was diagnosed in a two year
old infant (son 2) characterized by hypochromic, microcytic anaemia,
very low MCV, low serum iron and low transferrin saturation and
very low ferritin levels. Despite oral Fe therapy 5 mg/kg/day over
four months no response of reticulocytes or hemoglobin was
observed. Poor compliance or incorrect medication/dose was
excluded. Usual reasons for microcytic anaemia such as chronic
blood loss, gastrointestinal disease-like celiac disease, thalassemia,
concurrent chronic illness or sideroblastic anaemia were excluded.
Further laboratory investigations of other family members
revealed that also two one year old unidentical female twins
suffered from iron-refractory iron deficiency anaemia (Table 1).
Because of a marginally low birth weight daughter 1 (2045 g) and
daughter 2 (2550 g) (gestational age 37 weeks) received iron
supplements during the whole first year of life [28]. The twin
daughters received four intravenous infusions of 15 mg iron(III)-
hydroxide-saccharose-complex (VenoferH), Son 2 was treated with
four intravenous infusions of 50 mg each. These infusions resulted
in a significant rise in hemoglobin and normalization of iron status
in all three patients. Laboratory parameters at baseline and after
four intravenous iron infusions on day +108 and day +152,
respectively, as well as serum hepcidin levels are shown in Table 1.
The 7 year old son (son 1) and their parents did not suffer from
anaemia (Table 1). None of the six family members received blood
transfusions or recombinant human erythropoietin at least three
months before study entry. Written informed consent was
obtained to take additional blood samples for determination of
iron parameters and genetic analyses during a routine blood draw.
The study was approved by the local ethics committee at the
Medical University of Innsbruck (Approval-Nr. UN3256).
Measurement of iron status
Blood samples were drawn on a routine basis and laboratory
parameters, e.g. hemoglobin, red blood cell count and serum iron
parameters were determined by routine laboratory tests. Serum
specimens were drawn during this routine examination and stored
at 280uC until determination of serum hepcidin by a combination
of weak cation exchange chromatography and time-of-flight mass
spectrometry (TOF-MS), using a Microflex LT matrix-enhanced
laser desorption/ionisation TOF-MS platform (Bruker Daltonics,
Bremen, Germany) [29]. An internal standard (synthetic hepcidin-
24; Peptide International Inc., Louisville, KT, USA) was used for
quantification [29,30].
Sequencing of exons in SLC11A2 and TMPRSS6
Genomic DNA was extracted from peripheral blood collected
on EDTA on a BioRobot EZ1 advanced Workstation with the
EZ1 DNA blood kit (QIAGEN, Hilden, Germany) and quantified
with a NanoDrop spectrophotometer (Thermo Fisher Scientific
Inc., Waltham, MA).
Seventeen exons of the SLC11A2 gene (following the nomen-
clature of transcript ENST00000262051, Ensembl Release 58;
www.ensembl.org) were amplified in 16 PCR reactions (Table S1)
and sequenced with 32 primers (Table S2). The sequenced exons
and exon-intron boundaries of SLC11A2 summed up to a total of
8678 bp. An overview of the amplification and sequencing
strategy of the exons within SLC11A2 is given in Figure S1. A
detailed description can be found in Text S1.
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we used transcript ENST00000346753, which described 16 exons;
however, transcript ENST00000381792 included another exon
located between Exon 16 and Exon 17 in transcript
ENST00000346753. Therefore, we included this exon and
renamed it ‘‘Exon 16a’’. The sequenced exons and exon-intron
boundaries of TMPRSS6 summed up to a total of 7075 bp. An
overview of the amplification and sequencing strategy of the exons
within TMPRSS6 is given in Figure S2. Amplification and
sequencing primers are given in Tables S3 and S4.
Electrophoretic separation was carried out on an ABI3130xl
capillary sequencer with POP-7 and a 36 cm capillary array.
Single nucleotide polymorphism (SNP) genotyping in the
SAPHIR study
For replication of the identified variants, four SNPs within
SLC11A2 (rs6580779, rs161044, rs150909, rs149411) and three
SNPs within TMPRSS6 (rs11704654, rs4820268, rs855791) were
genotyped in a multiplex-format with the iPLEXH Gold assay on a
MassARRAY Analyzer 4 platform (SEQUENOM, Hamburg,
Germany) in the SAPHIR study. The Salzburg Atherosclerosis
Prevention Program in Subjects at High Individual Risk
(SAPHIR) is an observational study conducted in the years
1999–2002 involving 1,770 healthy unrelated subjects: 663
females from 39 to 67 years of age and 1,107 males from 39 to
66 years of age [31,32]. DNA was available for 1,726 samples.
Study participants were recruited by health screening programs in
large companies in and around the city of Salzburg. The fraction
of samples that were genotyped twice for quality assurance were
4%, the genotyping discordance rate was 0.
Replication in the NBS study
As an additional replication, the identified variants in TMPRSS6
and SLC11A2 were also analyzed in 1,832 samples of the
Nijmegen Biomedical Study (NBS) for which both genotype data
(Illumina HumanHap370CNV-DuoBeadChip) and iron and
ferritin measurements were available. Details of the Nijmegen
Biomedical Study (NBS) have been described before [33]. Briefly,
the NBS is a population-based survey conducted by the
Department of Epidemiology, Biostatistics, and HTA and the
Department of Laboratory Medicine of the Radboud University
Nijmegen Medical Centre, The Netherlands. Approval to conduct
the study was obtained from the Radboud University Nijmegen
Medical Centre Institutional Review Board.
Genotype data for SNPs rs4820268, rs855791 and rs149411
were present on the applied genome-wide BeadChip and were
extracted for the purpose of this study. Genotype data for SNPs
rs11704654, rs6580779, rs161044 and rs150909 were imputed
(with CEU HapMap phase II as a reference sample) and extracted
and transformed to hard calls using a probability threshold of 0.9.
Table 1. Laboratory parameters of the family at the time of taking of the first blood samples, and after intravenous iron
administrations in the family’s children suffering from IRIDA, i.e. Son 2, and Daughters 1 and 2.
Adult reference
ranges (m/f)
a Father Mother
Children ref.
ranges Son 1 Son 2 Daughter 1 Daughter 2
Age [y] 41 34 7 2 1 1
Hb [g/l] Baseline m:135–175/ 139 141 115–155 133 84 81 89
After Fe substitution f: 120–160 126 105 109
MCHC [g/l] Baseline 310–370 335 326 300–600 339 296 298 304
After Fe substitution 344 329 328
MCV [fl] Baseline 80–100 94 83 78–102 83 56 58 57
After Fe substitution 73 69 61
Serum iron [mg/l] Baseline m:11–28 17.7 18.4 22–184 22.2 2.7 2.8 ,0.9
After Fe substitution f:7–26 16.6 18.6 5.7
Serum ferritin [mg/l] Baseline m:30–400/ 48 33 15–200 18 ,3 ,3 ,3
After Fe substitution f:15–150 41 11 25
Serum hepcidin [ng/l]
b Baseline m:0.5–11.0 ,1.0 ,1.0 n.a. 1.6 n.a. ,1 ,1
After Fe substitution f:0.5–15.2
b n.a. n.a. n.a.
Transferrin saturation (%) Baseline 16–45% 29% 32% 7–46% 26% 3% 3% ,2%
After Fe substitution 27% 21% 7%
Transferrin [mg/dl] Baseline 200–360 244 230 200–360 336 392 408 154
After Fe substitution 242 325 310
Leucocytes [G/l] Baseline 4.5–11 9.9 4.2 6–17.5 7.8 8.5 9.1 21.8
After Fe substitution 6.3 8.5 7.1
Platelets [G/l] Baseline 150–400 375 228 150–400 401 428 665 752
After Fe substitution 320 439 308
Notes:
aIf reference values are different for males (m) and females (f), both reference values are indicated.
bReference values can be found at www.hepcidinanalysis.com (date of consulting the website: January 24, 2012);
n.a. not available.
doi:10.1371/journal.pone.0035015.t001
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Expectations between two unrelated variables were tested for
equality using a Mann-Whitney-U-test. To indicate the strength
and direction of a linear relationship between two random
variables, Spearman’s rho correlation coefficient was measured.
Linear regression was used to model the relationship between the
seven analyzed SNPs and iron as well as ferritin levels in the
SAPHIR population; adjustments were made for age and gender
by adding them as additive covariates into the regression models.
Both outcome variables were log-transformed, since their
distribution was skewed. Therefore, p-values from single SNP
and haplotype analysis are based on the log-transformed model.
For better interpretability, beta-estimates of the regression models
are based on the original scale of iron and ferritin. To adjust for
multiple testing, Bonferroni correction was applied to the number
of effective loci calculated by the algorithm proposed by Li et al.
[34]. As 5 out of 7 SNPs turned out to be effective loci, we
assumed p-values,0.01 as significant.
Haplotypes within TMPRSS6 and SLC11A2 for the family
members could be derived unambiguously, since there was one
family member for each locus, who was heterozygote at no more
than one locus (the father for TMPRSS6) or who was homozygote
at all loci (son 1 for SLC11A2). All other haplotype combinations
could be concluded from these. Haplotypes in the SAPHIR study
were derived using the EM algorithm implemented in the
haplo.stats package in R. Subsequently, haplotypes were allocated
to individuals by taking the most probable one. By using these
‘‘best guess’’ haplotypes, it was possible to also look at the specific
haplotype combinations, which were present in the family
members. Regression models were calculated for the specific
haplotype-pairs in TMPRSS6 and SLC11A2, and for the
combination of haplotype pairs in both genes. For the haplotype
pairs in SLC11A2 and TMPRSS6, the regression was performed on
all haplotype pairs in one model with the most probable haplotype
pair as the reference. For the combined analysis, the particular
haplotype-pairs of interest were tested versus all other pairs. Each
of the regression models (on iron and ferritin) was adjusted for age
and sex. In the haplotype analysis, for both genes, all haplotype
pairs were tested in one regression model against a reference
haplotype pair. Therefore, within each haplotype regression
model, there was no need for correcting for multiple testing
anyway.
Statistical analyses were performed with SPSS (version 18, SPSS
Inc., Chicago, Illinois) and R (version 2.14.1).
Bioinformatic analysis
Following functional considerations based on the SNP position,
the potential effects of the 7 SNPs were investigated using selected
bioinformatic applications [35]. An extended description can be
found in Text S2.
Results
In the present paper, we report the clinical case of three siblings
with severe iron deficiency anaemia being refractory to oral iron
substitution. Given the wealth of publications describing mutations
in two genes (SLC11A2 and TMPRSS6) being associated with iron
deficiency anaemia [8–10,13,15,16,36,37], we initially hypothe-
sized that mutations in these two candidate genes were the reason
for this anaemia. Sequencing of the exons and exon–intron
boundaries of both SLC11A2 and TMPRSS6 revealed seven known
SNPs to occur in the family, but no novel mutations. No allele
clearly segregated with the IRIDA trait in this family.
Four SNPs were found within SLC11A2: rs6580779, rs161044,
rs150909, and rs149411. All family members except for the first
son were heterozygotes for these SNPs (Table 2). Given the length
of 8678 bp of non-redundant sequence information, we found one
SNP in 2170 bp. Within the entire gene region of SLC11A2 of
,50 kb, ,730 SNPs were found in dbSNP (build 135).
Although mutations in TMPRSS6 are described to be linked to
severe iron deficiency anaemia in patients with relatively increased
hepcidin levels, we decided to sequence the exons and exon–intron
boundaries of the TMPRSS6 gene. We found three SNPs:
rs11704654, rs4820268, and rs855791 (Table 2). Given the length
of 7075 bp of non-redundant sequence information, we found one
SNP in 2358 bp. Within the entire gene region of TMPRSS6 of
,44 kb, ,784 SNPs were described in dbSNP (build 135). The
SNP rs855791 results in a nonsynonymous (V736A) change in the
serine protease domain of TMPRSS6 and was recently described as
the top-hit of genome-wide association studies (GWAS) to be
associated with alterations of serum iron, transferrin saturation,
erythrocyte mean cell volume, blood hemoglobin levels, and
glycated hemoglobin [23,26,38]. Similarly, rs4820268, located in
exon 13, was associated with lower serum iron concentrations,
lower hemoglobin levels, smaller red cells, and more variability in
red cell size [24]. This variant was also discussed to have a
lowering effect on hepcidin levels in urine [25].
We genotyped the seven SNPs in the population-based
SAPHIR study (n=1,726) and replicated them in NBS
(n=1,832) and found that the TMPRSS6-SNPs were very frequent
in these populations, but that the three SNPs in SLC11A2 occurred
at minor allele frequencies of 6.1% (Table 3). In addition, the
SNPs rs6580779, rs161044, and rs150909 were highly correlated
with each other, although they were dispersed over the entire gene
region of ,40 kb (Figure S3). Due to this correlation structure, the
number of effective loci was calculated to be 5 out of the 7 SNPs.
Therefore, the significance level for the single genotype analysis
was set to 0.01.
When performing genetic association analysis of these seven
SNPs with either iron or ferritin levels in the SAPHIR population,
we found that only the two top-hit SNPs of recent GWAS on iron
levels [23,24,26] (rs4820268 and rs855791) exhibited a slight,
though significant effect on iron and ferritin (Table 4). These
associations remain significant even after correction for multiple
testing. The remaining five SNPs showed no influence on the
analyzed outcome variables. Since rs4820268 and rs855791 were
highly correlated (D’=0.95, r
2=0.83), they rather reflect the same
information. In order to test for a possible interaction of the only
two significant SNPs rs4820268 and rs855791 on both iron and
ferritin levels, we introduced the interaction term
rs4820268*rs855791 to the linear regression model, but it was
neither significant on iron (p=0.469) nor on ferritin levels
(p=0.686). Therefore, we could not detect an epistatic effect of
these two SNPs on iron-related traits.
The haplotypes of all family members within TMPRSS6 and
SLC11A2 are summarized in Table S5 together with the haplotype
frequencies in SAPHIR. Interestingly, the most common
TMPRSS6-haplotypes in SAPHIR was not observed in the family
members. When combining the haplotypes to haplotype pairs as
observed in family members, the TMPRSS6 haplotype-pair of son
2 showed significantly reduced iron values as well as ferritin levels
(Table 5). The corresponding individuals from the SAPHIR
population (n=6) showed markedly reduced iron as well as ferritin
values than the average SAPHIR population (Table S6).
Finally, when we combined the TMPRSS6 and SLC11A2
genotypes to a joint profile, we saw that the one SAPHIR
individual exhibiting the profile of the anaemic son had extremely
SLC11A2 & TMPRSS6 in a Family with Severe Anaemia
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th percentile of the iron
and ferritin level distribution in SAPHIR. This individual
exhibited also the same combination of TMPRSS6 and SLC11A2
haplotype-pairs as son 2, which was also associated with lower iron
and ferritin levels (Table 5). Although this analysis is only based on
one person, the laboratory parameters are in line with the
observations made in the family.
However, this observation could not be confirmed in the
Nijmegen Biomedical Study [39]. Although the NBS population
was of similar size as the SAPHIR study, the SLC11A2/TMPRSS6-
profile of the anaemic son was not observed (Table S7).
Taken together, neither the single SNP effects nor the
haplotypes could explain the observed phenomenon that both
the family and unrelated individuals carrying the family’s joint
TMPRSS6/SLC11A2-profiles in SAPHIR showed reduced iron
and ferritin levels.
Bioinformatic analysis
Bioinformatic analysis of the 7 SNPs was inconclusive and did
not provide an evident candidate SNP (Table S8).
The most promising SNP for SLC11A2 was rs6580779, which
was predicted to affect a ‘‘motif ten element’’ (MTE), which are
core promoter elements located between 18 and 27 nucleotides
downstream of the transcriptional initiator element [40]. The SNP
rs150909 was predicted to affect a binding site for the micro-RNA
star form miR-106a* [41].
All TMPRSS6 SNPs affected the coding region and rs855791
produced a conservative amino acid exchange, which was
concordantly predicted to be benign. Also the Grantham matrix
score of 64 for a Valine to Alanine substitution pointed towards a
rather benign effect [42]. Furthermore, also the synonymous
TMPRSS6 SNPs were predicted to have considerable functional
consequences by affecting splicing regulation elements, mRNA
stability or translation efficiency [43]. Unfortunately, the in-silico
prediction of these effects is, however, challenging and the
Table 2. SNP genotypes of the family within the two genes SLC11A2 and TMPRSS6.
SLC11A2 TMPRSS6
rs6580779 rs161044 rs150909 rs149411 rs11704654 rs4820268 rs855791
Chromosome:Base pair position 12:51420164 12:51382232 12:51381077 12:51380232 22:37499386 22:37469591 22:37462936
Located in: 59UTR Intron 39UTR 39UTR Exon 2 Exon 13 Exon 17
Ancestral/derived allele: A/C C/T T/C A/G C/T A/G G/A
SNP effect: ----S y n . S y n . V 7 3 6 A
Father 1111012
M o t h e r 1111211
S o n 1 0000101
S o n 2 1111112
D a u g h t e r 1 1111101
D a u g h t e r 2 1111111
Coding of genotypes
0= AA CC TT GG CC AA GG
1= AC CT TC GA CT AG GA
2= CC TT CC AA TT GG AA
doi:10.1371/journal.pone.0035015.t002
Table 3. SNP genotyping results in SAPHIR (n=1,726) and NBS (n=1,832).
SLC11A2 TMPRSS6
Genotype rs6580779 rs161044 rs150909 rs149411 rs11704654 rs4820268 rs855791
0 88.1/88.7% 88.0/88.7% 88.0/88.7% 34.9/38.1% 66.4/66.2% 30.2/27.1% 33.0/29.1%
1 11.6/10.7% 11.7/10.7% 11.7/10.7% 49.3/46.5% 29.8/30.1% 48.9/51.5% 48.0/50.8%
2 0.3/0.6% 0.3/0.6% 0.3/0.6% 15.7/15.4% 3.9/3.7% 20.9/21.4% 19.0/20.1%
MAF 6.1/6.0% 6.1/6.0% 6.1/6.0% 40.4/38.7% 18.8/18.7% 45.4/47.2% 43.0/45.5%
CR 99.2/99.9% 99.7/99.9% 99.7/99.9% 99.5/99.9% 99.7/95.6% 98.8/99.7% 98.7/100%
HWE 0.348/0.089 0.539/0.089 0.538/0.089 0.311/0.431 0.313/0.638 0.552/0.159 0.408/0.323
Notes:
The coding of genotypes is indicated in Table 2. SAPHIR data are indicated on the left side of the slash, and NBS data are given on the right side of the slash.
MAF… minor allele frequency.
CR… call rate (genotyping success rate).
HWE… p-value for test for Hardy-Weinberg-Equilibrium.
doi:10.1371/journal.pone.0035015.t003
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regulation elements is still improvable [44].
Discussion
The children reported in the present study showed all features of
iron deficiency anaemia, especially the inability to respond to oral
iron administration. Interestingly, neither the father nor the
mother was anaemic, but both were borderline iron-deficient,
which is also reflected by low or undetectable serum hepcidin
levels. This observation is in line with previous reports that the
degree of anaemia is more evident in infancy than during adult life
[16,45].
In accordance, the results of our comparative observation with
the SAPHIR study indicated that adult individuals from the
SAPHIR population with identical SNP combinations and
haplotypes as seen in the children of the family under investigation
in this study had low iron levels but not that severe iron deficiency
as seen in the children. These discrepancies might thus possibly be
attributed to the fact that iron parameters of very young children
were compared with adults and that the phenotype could only be
seen in case of high iron demand as it occurs in early childhood
and adolescence where high amounts of the metal are needed for
haemoglobin synthesis and growth. This also fits to observations
made in TMPRSS6 mutated subjects which have been shown to
give a more severe phenotype in young children and which
becomes milder with aging [16,36].
The results of the haplotype analyses indicated that the
combined SLC11A2/TMPRSS6 haplotype of SON 2 was signifi-
cantly associated with lowered iron and highly significantly
associated with lowered ferritin values in SAPHIR. Unfortunately,
we could not replicate this finding, as the SLC11A2/TMPRSS6
Table 4. Genetic association between iron and ferritin levels and SNPs in SLC11A2 and TMPRSS6 in SAPHIR.
Iron [mg/dl] Ferritin [mg/l]
SNP AA Aa aa b 95% CI p-value AA Aa aa b 95% CI p-value
rs6580779 (SLC11A2) 100.23 98.82 97.41 21.41 (26.11–3.29) 0.567 175.30 166.62 157.94 28.68 (235.03–17.67) 0.108
rs161044 (SLC11A2) 100.23 98.57 96.90 21.67 (26.34–3.01) 0.506 175.77 167.09 158.40 28.68 (234.86–17.50) 0.102
rs150909 (SLC11A2) 100.25 98.57 96.89 21.68 (26.36–2.99) 0.503 175.51 167.02 158.53 28.48 (234.66–17.69) 0.107
rs149411 (SLC11A2) 100.76 99.84 98.93 20.91 (23.19–1.37) 0.564 175.80 174.55 173.29 21.25 (214.07–11.56) 0.534
rs11704654 (TMPRSS6) 100.44 99.40 98.37 21.03 (23.83–1.78) 0.675 173.97 175.99 178.01 2.02 (213.65–17.70) 0.569
rs4820268 (TMPRSS6) 104.61 99.58 94.54 25.03 (27.24–22.82) 3.9E-6 191.17 172.98 154.78 218.19 (230.62–25.75) 0.001
rs855791 (TMPRSS6) 104.60 99.41 94.22 25.19 (27.40–22.96) 2.0E-6 187.97 171.86 155.75 216.10 (228.60–23.61) 0.002
Note: For linear regression, an additive genetic effect of the SNPs on the outcome variable was assumed; linear regression analyses were adjusted for age and gender.
The p-values were based on the log-transformed model, and the b-estimates were based on the model on the original scale.
doi:10.1371/journal.pone.0035015.t004
Table 5. Genetic association between iron and ferritin levels and haplotype-pairs in SLC11A2 and TMPRSS6 in SAPHIR.
Gene Family member Haplotype pair N Iron Ferritin
b p-value b p-value
SLC11A2 Reference ACAC/ACAT 776 – – – –
Son 1 ACAC/ACAC 600 20.8251 0.614 210.2684 0.638
All others ACAC/CTGT 123 21.3861 0.577 210.1689 0.241
TMPRSS6 Reference CAC/CGT 551 – – – –
Father CGT/CAT 13 7.4050 0.32302 215.080 0.5242
Mother TGT/TAC 30 23.2822 0.85529 20.153 0.4125
Son 1 & Daughter 1 TAC/CAT 4 2.1344 0.92762 2.234 0.5159
Son 2 TGT/CAT 6 234.115 0.00278 275.317 0.0387
Daughter 2 CGT/TAC 0 Not present Not present
SLC11A2/TMPRSS6 Father ACAC/CTGT; CGT/CAT 1 28.65582 0.9257 10.7409 0.712
combined Mother ACAC/CTGT; TGT/TAC 0 Not present Not present
Son 1 ACAC/ACAC; TAC/CAT 1 250.7302 0.0630 2131.511 0.566
Son 2 ACAC/CTGT; TGT/CAT 1 260.555 0.0128 2260.230 9.57e-05
Daughter 1 ACAC/CTGT; TAC/CAT 0 Not present Not present
Daughter 2 ACAC/CTGT; CGT/TAC 0 Not present Not present
Notes: For the haplotype pairs in SLC11A2 and TMPRSS6, the regression was performed on all haplotype pairs in one model with the most probable haplotype pair as
the reference. For the combined analysis, each line reflects the results from a regression model of this particular haplotype-pair versus all other pairs on the traits (each
model sex- and age-adjusted). The p-values are based on the log-transformed model; the b-estimates are based on the model on the original scale.
doi:10.1371/journal.pone.0035015.t005
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Study. However, it would be interesting to validate this finding in
further populations.
Although GWAS have been very successful at identifying risk
alleles for complex genetic traits, there still remains the fact that
the identified risk alleles for a particular trait, together, don’t fully
explain the trait heritability. The results of our study fit well into
this observation. Various explanations for this missing-heritability
problem have been proposed, but a recent study by Song et al.
[46] supports the idea that perhaps this heritability is not missing
at all, or at least not completely. Typically, the risk information
from multiple alleles is combined by using a multiplicative model,
thereby assuming that the individual loci behave independently.
Song et al., however, calculated recurrence risks to close relatives
under different models and found that the results yielded higher
estimated recurrence risks than were predicted under a multipli-
cative model, particularly when the risk alleles were rare [46]. This
indicates that gene-gene interactions could account for more
heritability than is often assumed. The empirical data from our
family study confirm the results of Song and colleagues [46], thus
implying that gene-gene interactions might account for an
important section of the missing heritability of complex diseases.
In addition to gene-gene interactions one has also to consider
interaction of the gene products at the protein level, which is a
form of epistatic interaction, as has recently been shown for DMT1
and hepcidin [47].
With this in mind, we hypothesized that the combined
impairment of SLC11A2 and TMPRSS6 activities by the different
polymorphisms effected both transmembrane iron-flux and
hepcidin regulation which in summary would lead to the iron-
deficient phenotype in situations with an increased iron demand
(growth phase of children).
Although our data are suggestive for a gene-gene interaction,
based on the methodology used, one cannot fully exclude another
gene defect that might contribute to the dramatic anaemia in the
children which might be identified by whole exome sequencing.
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